Foxo Technologies Inc Revenue Growth Rates (FOXO), Current and Historic Growth - CSIMarket
CSIMarket
 


Foxo Technologies Inc   (FOXO)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

FOXO's Revenue Growth by Quarter and Year

Foxo Technologies Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/FOXO/growth
https://api.csimarket.com/api/v1/companies/FOXO/fundamentals
https://api.csimarket.com/api/v1/companies/FOXO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
FOXO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 7.00
2nd Quarter June 4.72
1st Quarter March 7.70
FY 19.42

FOXOs Annual Revenue
Foxo Technologies Inc 's Revenue in the fiscal year 2025 $ 24.70 millions
Foxo Technologies Inc 's Revenue in the fiscal year 2024 $ 6.54 millions
Foxo Technologies Inc 's Revenue in the fiscal year 2023 $ 0.15 millions
Foxo Technologies Inc 's Revenue in the fiscal year 2022 $ 0.51 millions
Foxo Technologies Inc 's Revenue in the fiscal year 2021 $ 0.12 millions




FOXO Revenue third quarter 2026 Y/Y Growth Comment
Foxo Technologies Inc reported Revenue improvement of 24.62% year on year in the third quarter 2026, to $ 7.00 millions, this is lower than Foxo Technologies Inc 's recent average Revenue surge of 7129.35%.

Looking into third quarter 2026 results within Medical Laboratories industry 32 other companies have achieved higher Revenue growth. While Foxo Technologies Inc ' s Revenue rise of 24.62% ranks overall at the positon no. 3734 in the third quarter 2026.




FOXO Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 24.62 %
2nd Quarter June -34.35 %
1st Quarter March 51.87 %
FY   -

Financial Statements
Foxo Technologies Inc 's third quarter 2026 Revenue $ 7.00 millions FOXO's Income Statement
Foxo Technologies Inc 's third quarter 2025 Revenue $ 5.62 millions Quarterly FOXO's Income Statement


FOXO Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 48.39 %
2nd Quarter June -38.7 %
1st Quarter March 13.07 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #33
Healthcare Sector #505
Overall #3734

Revenue Y/Y Growth Statistics
High Average Low
72383.66 % 7129.35 % -73.68 %
(Jun 30 2025)   (Dec 31 2023)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #33
Healthcare Sector #505
Overall #3734
Revenue Y/Y Growth Statistics
High Average Low
72383.66 % 7129.35 % -73.68 %
(Jun 30 2025)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Foxo Technologies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4171.43 % 439.06 % -96.89 %
(Sep 30 2024)  


FOXO's III. Quarter Q/Q Revenue Comment
Foxo Technologies Inc achieved in the III. Quarter 2026 below company average Revenue jump of 48.39% quarter on quarter, to $ 7.00 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -21.84% in the III. Quarter a year ago.

Within Medical Laboratories industry 32 other companies have achieved higher Revenue quarter on quarter growth. While Foxo Technologies Inc 's Revenue growth quarter on quarter, overall rank is 3580.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #33
Healthcare Sector #502
Overall #3580
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #33
Healthcare Sector #502
Overall #3580
Revenue Q/Q Growth Statistics
High Average Low
4171.43 % 439.06 % -96.89 %
(Sep 30 2024)  


FOXO's III. Quarter Q/Q Revenue Comment
Foxo Technologies Inc achieved in the III. Quarter 2026 below company average Revenue jump of 48.39% quarter on quarter, to $ 7.00 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -21.84% in the III. Quarter a year ago.

Within Medical Laboratories industry 32 other companies have achieved higher Revenue quarter on quarter growth. While Foxo Technologies Inc 's Revenue growth quarter on quarter, overall rank is 3580.


Foxo Technologies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 26.23
Y / Y Revenue Growth (TTM) 26.71 %
Year on Year Revenue Growth Overall Ranking # 5
Seqeuential Revenue Change (TTM) 5.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 204


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Foxo Technologies Inc 's cumulative twelve months Revenue were $ 26 millions, company would post below average annual Revenue growth of 5.59% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Foxo Technologies Inc 's Revenue growth from the 4.72% growth in Jun 30 2026.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3 to 5.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 4
Healthcare Sector # 3
Overall # 5

Revenue TTM Y/Y Growth Statistics
High Average Low
10405.91 %
1977.54 %
-71.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 58
S&P 500 # 204
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Foxo Technologies Inc 's cumulative twelve months Revenue were $ 26 millions, company would post below average annual Revenue growth of -71.62% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Foxo Technologies Inc 's Revenue growth from the 4.72% growth in Jun 30 2026.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3 to 5.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 4
Healthcare Sector # 3
Overall # 5

Revenue TTM Y/Y Growth Statistics
High Average Low
10405.91 %
1977.54 %
-71.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 58
S&P 500 # 204




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FOXO's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Cardiff Oncology Inc 42.50%$ 42.500 millions
Nexgel Inc 41.73%$ 41.730 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Escalon Medical Corp 38.81%$ 38.811 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Dariohealth Corp 32.28%$ 32.279 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions


About Foxo Technologies Inc Revenue Growth Rates (FOXO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Foxo Technologies Inc (CIK 1812360).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-052167
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Foxo Technologies Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.